SOURCES SOUGHT
65 -- Oseltamivir Phosphate
- Notice Date
- 1/18/2018
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- SPE2DP-18-R-0110
- Archive Date
- 3/7/2018
- Point of Contact
- Christina Izzi, Phone: 215-737-8740
- E-Mail Address
-
Christina.Izzi@dla.mil
(Christina.Izzi@dla.mil)
- Small Business Set-Aside
- N/A
- Description
- The Defense Logistics Agency Troop Support is seeking sources capable of providing Oseltamivir Phosphate. DLA Troop Support is contemplating awarding a requirements contract with a one-year base period for Oseltamivir Phosphate 75MG Capsules in bottles of 10 each. The estimated quantity to be ordered is 875,000 bottles. However this quantity may increase or decrease as requirements change. Must have FDA approval to sell Oseltamivir Phosphate before award of the contract. If your firm currently manufactures or distributes Oseltamivir Phosphate, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements g) Product shelf life (Months) *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture Oseltamivir Phosphate or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Oseltamivir Phosphate. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this FRI may be submitted electronically in pdf format and emailed to christina.izzi@dla.mil.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/SPE2DP-18-R-0110/listing.html)
- Record
- SN04793260-W 20180120/180118231343-cc39dfc7b5cf7bd917fa7272432039e6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |